In 2022, 1.9 million patients are estimated to be diagnosed with cancer in the United States. Biomarker testing is becoming increasingly important to cancer care because it helps providers tailor cancer treatment when actionable biomarkers are present. While guidelines exist, insurance coverage of biomarker testing varies widely. We examined administrative claims data to understand the premium impact of expanding biomarker testing coverage in the commercial and Medicaid markets. We discuss the:
- Current landscape of biomarker testing coverage
- Development of benchmarks for biomarker testing coverage
- Impact on 2022 member premiums
This report was commissioned by the American Cancer Society Cancer Action Network.
